Clinical trials: Secondary Insomnia
Primary Insomnia, Secondary Insomnia
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.
- Trial name
- SLUMBER (NCT00784875)
- Testing
- LY2624803, zolpidem
- Where
- 49 sites in United States
- Volunteers
- 643 people
- Sponsor
- Eli Lilly and Company
Insomnia, Secondary, Sleep Disturbance
Robustness and Usability of the Dreem 3 System for at Home Sleep Monitoring in an Insomnia Population.
There is an unmet medical need for monitoring sleep for multiple nights in a patient's home, without the inconvenience of traveling and staying overnight in a medical center, and without the need for a technician to set up a…
- Conditions
- Insomnia, Secondary, Sleep Disturbance, Sleep, Sleep Initiation and Maintenance Disorders
- Trial name
- NCT05611099
- Testing
- Dreem 3 System vs WatchPAT One, Usability Questionnaire
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Dreem
Substance Use, Stress
Automating Peer Learning to Reduce Alcohol Use and Related Deviant Behavior in Secondary School
Deviant peer affiliation is one of the most important predictors of alcohol use in adolescence. These affiliations arise when socially marginalized youth self-aggregate and reinforce alcohol use and other deviant activity (i.e.…
- Conditions
- Substance Use, Stress, Relation, Interpersonal, Bullying
- Trial name
- PeerLearning (NCT04478240)
- Testing
- PeerLearning.net
- Where
- United States
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Insomnia
Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause
To demonstrate improved subjective sleep in women with insomnia secondary to perimenopause or menopause following treatment with 3 mg of eszopiclone.
- Trial name
- NCT00366093
- Testing
- Eszopiclone
- Where
- 51 sites in United States
- Volunteers
- 410 people
- Sponsor
- Sumitomo Pharma America, Inc.